Bioptimus appoints Julie Gerardi as Chief Commercial Officer

Bioptimus, a leading AI company building the first universal AI foundation model for biology, is thrilled to announce the appointment of biotech veteran Julie Gerardi as its Chief Commercial Officer. Ms. Gerardi joins Bioptimus with an extensive track record in building pioneering life science businesses, bringing more than 25 years of experience in both start-up and Fortune 500 companies.

Ms. Gerardi brings deep expertise in the drug and biomarker discovery space. A biochemist by training, Ms. Gerardi has an impressive track record in leading commercial teams in the life sciences space. She joins Bioptimus from Parse Biosciences, a leading provider of scalable single-cell sequencing used to fuel foundational datasets, where she served as Vice President of Business Development and Strategy. Prior to that she served as VP of Business Development at Tempus AI, overseeing commercial operations and the build-up of their biological modeling and tumor organoid programs.

As Bioptimus’s new Chief Commercial Officer, Ms. Gerardi will focus on deepening relationships with strategic partners in the pharmaceutical and biological research sectors, and on building robust commercial go-to-market strategies - driving the company’s mission to fuel breakthroughs in biomedicine and beyond. Her expertise in building high-impact, purpose-driven ventures positions her to lead Bioptimus through its next phase of innovation and revenue expansion.

Ms. Gerardi said:

"I am proud and humbled to be given the opportunity to join the incredible team at Bioptimus. Bioptimus is building foundation models that demystify the building blocks of life, from cells to systems at scales never before imagined. H-Optimus-1, with billions of high-quality data points, is a powerful foundation, elucidating patterns and signatures that prior models could not power – that's exciting!"

David Cahané, General Manager and Co-Founder of Bioptimus, added:

"We are thrilled to welcome Julie to Bioptimus as our commercial head. Her exceptional background in translating cutting-edge biological technologies into commercial success makes her the ideal leader to drive our next phase of growth. She brings a deep commitment and belief in the potential of generative AI to provide new insights to researchers and better treatments for patients."

‍